Preventing local regeneration of glucocorticoids by 11beta-hydroxysteroid dehydrogenase type 1 enhances angiogenesis
- PMID: 16093320
- PMCID: PMC1189304
- DOI: 10.1073/pnas.0500641102
Preventing local regeneration of glucocorticoids by 11beta-hydroxysteroid dehydrogenase type 1 enhances angiogenesis
Abstract
Angiogenesis restores blood flow to healing tissues, a process that is inhibited by high doses of glucocorticoids. However, the role of endogenous glucocorticoids and the potential for antiglucocorticoid therapy to enhance angiogenesis is unknown. Using in vitro and in vivo models of angiogenesis in mice, we examined effects of (i) endogenous glucocorticoids, (ii) blocking endogenous glucocorticoid action with the glucocorticoid receptor antagonist RU38486, and (iii) abolishing local regeneration of glucocorticoids by the enzyme 11beta-hydroxysteroid dehydrogenase type 1 (11betaHSD1). Glucocorticoids, administered at physiological concentrations, inhibited angiogenesis in an in vitro aortic ring model and in vivo in polyurethane sponges implanted s.c. RU38486-enhanced angiogenesis in s.c. sponges, in healing surgical wounds, and in the myocardium of mice 7 days after myocardial infarction induced by coronary artery ligation. 11betaHSD1 knockout mice showed enhanced angiogenesis in vitro and in vivo within sponges, wounds, and infarcted myocardium. Endogenous glucocorticoids, including those generated locally by 11betaHSD1, exert tonic inhibition of angiogenesis. Inhibition of 11betaHSD1 in liver and adipose has been advocated to reduce cardiovascular risk in the metabolic syndrome: these data suggest that 11betaHSD1 inhibition offers a previously uncharacterized therapeutic approach to improve healing of ischemic or injured tissue.
Figures



Similar articles
-
Contribution of endogenous glucocorticoids and their intravascular metabolism by 11β-HSDs to postangioplasty neointimal proliferation in mice.Endocrinology. 2012 Dec;153(12):5896-905. doi: 10.1210/en.2012-1481. Epub 2012 Nov 2. Endocrinology. 2012. PMID: 23125311 Free PMC article.
-
Intravascular glucocorticoid metabolism during inflammation and injury in mice.Endocrinology. 2007 Jan;148(1):166-72. doi: 10.1210/en.2006-0996. Epub 2006 Sep 28. Endocrinology. 2007. PMID: 17008390
-
11β-hydroxysteroid dehydrogenase type 1 gene knockout attenuates atherosclerosis and in vivo foam cell formation in hyperlipidemic apoE⁻/⁻ mice.PLoS One. 2013;8(2):e53192. doi: 10.1371/journal.pone.0053192. Epub 2013 Feb 1. PLoS One. 2013. PMID: 23383297 Free PMC article.
-
Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 as a promising therapeutic target.Drug Discov Today. 2007 Jul;12(13-14):504-20. doi: 10.1016/j.drudis.2007.06.001. Epub 2007 Jun 27. Drug Discov Today. 2007. PMID: 17631244 Review.
-
11beta-hydroxysteroid dehydrogenase type 1 as a modulator of glucocorticoid action: from metabolism to memory.Trends Endocrinol Metab. 2004 Nov;15(9):418-24. doi: 10.1016/j.tem.2004.09.007. Trends Endocrinol Metab. 2004. PMID: 15519888 Review.
Cited by
-
Hypoxia Attenuates Pressure Overload-Induced Heart Failure.J Am Heart Assoc. 2024 Feb 6;13(3):e033553. doi: 10.1161/JAHA.123.033553. Epub 2024 Jan 31. J Am Heart Assoc. 2024. PMID: 38293923 Free PMC article.
-
11Beta-hydroxysteroid dehydrogenase-1 deficiency or inhibition enhances hepatic myofibroblast activation in murine liver fibrosis.Hepatology. 2018 Jun;67(6):2167-2181. doi: 10.1002/hep.29734. Epub 2018 Feb 22. Hepatology. 2018. PMID: 29251794 Free PMC article.
-
Safer topical treatment for inflammation using 5α-tetrahydrocorticosterone in mouse models.Biochem Pharmacol. 2017 Apr 1;129:73-84. doi: 10.1016/j.bcp.2017.01.008. Epub 2017 Jan 24. Biochem Pharmacol. 2017. PMID: 28131845 Free PMC article.
-
11β-hydroxysteroid dehydrogenases: intracellular gate-keepers of tissue glucocorticoid action.Physiol Rev. 2013 Jul;93(3):1139-206. doi: 10.1152/physrev.00020.2012. Physiol Rev. 2013. PMID: 23899562 Free PMC article. Review.
-
Steroid regulation of menstrual bleeding and endometrial repair.Rev Endocr Metab Disord. 2012 Dec;13(4):253-63. doi: 10.1007/s11154-012-9228-2. Rev Endocr Metab Disord. 2012. PMID: 23224720 Review.
References
-
- Kurotobi, T., Sato, H., Kinjo, K., Nakatani, D., Mizuno, H., Shimizu, M., Imai, K., Hirayama, A., Kodama, K. & Hori, M. (2004) J. Am. Coll. Cardiol. 44, 28-34. - PubMed
-
- Vernieri, F., Pasqualetti, P., Matteis, M., Passarelli, F., Troisi, E., Rossini, P. M., Caltagirone, C. & Silvestrini, M. (2001) Stroke 32, 1552-1558. - PubMed
-
- Hasan, Q., Tan, S. T., Gush, J., Peters, S. G. & Davis, P. F. (2000) Pediatrics 105, 117-120. - PubMed
-
- Aiello, L. P. & Wong, J. S. (2000) Kidney Int. Suppl. 77, S113-S119. - PubMed
-
- Siemann, D. W., Chaplin, D. J. & Horsman, M. R. (2004) Cancer 100, 2491-2499. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases